Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.

Starpharma today announces that after nearly 17 years with the Company, including 14 years as Chief Financial Officer (CFO), Mr Nigel Baade, has advised of his intention to leave Starpharma in early 2023 to pursue new professional opportunities. 

Starpharma today announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting today.

Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP^® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP^® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.

"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.

"Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform", as featured in Fierce Pharma. 

"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune.

Starpharma today announced it has signed a new DEP^® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP^® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP^® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.